Showing results (41-50 of 486) with videos related to
Sort By:
Pageof 49
European Journal of Haematology|August 1, 2024
Health-related quality of life in older hematological cancer survivors (70+) compared to older general population-A German cancer-register-based cross-sectional comparative studyFlorian Schatz, Anja Mehnert-Theuerkauf, Uwe Platzbecker, et al.Neoplasia (New York, N.Y.)|October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscapeSebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.Cancers|October 27, 2019
Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid LeukemiaMadlen Jentzsch, Sebastian Schwind, Enrica Bach, et al.Acta Haematologica|May 26, 2023
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension StudyMoshe Mittelman, Uwe Platzbecker, Sebastian Grosicki, et al.Frontiers in Medicine|September 7, 2021
Production and Application of CAR T Cells: Current and Future Role of EuropeVladan Vucinic, Andrea Quaiser, Philipp Lückemeier, et al.Current Pharmaceutical Design|February 27, 2016
Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic ImplicationsAnna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, et al.European Journal of Haematology|March 22, 2017
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidineMarkus Radsak, Uwe Platzbecker, Cornelia S Schmidt, et al.Molecular Aspects of Medicine|July 5, 2020
Iron overload and its impact on outcome of patients with hematological diseasesGeorg-Nikolaus Franke, Anne Sophie Kubasch, Michael Cross, et al.Annals of Hematology|August 13, 2013
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrowJudith Neukirchen, Uwe Platzbecker, Katja Sockel, et al.Current Treatment Options in Oncology|February 1, 2020
Use of Minimal Residual Disease in Acute Myeloid Leukemia TherapySebastian Schwind, Madlen Jentzsch, Enrica Bach, et al.Pageof 49